Osteopenia: what it means and what to ask

The key idea

Osteopenia describes bone density that is below normal but not as low as osteoporosis. The usual DXA definition is a T-score from -1.0 to -2.5. Osteoporosis is a T-score of -2.5 or lower.^1,2

That label should not be treated as either harmless or automatically dangerous. Some people naturally have lower bone density. Others develop osteopenia because of menopause, vitamin D deficiency, low calcium intake, low activity, medications, hormone problems, digestive conditions, or other secondary causes. FRAX was developed because fracture probability depends on more than BMD, including age, prior fracture, family history, smoking, glucocorticoids, rheumatoid arthritis, alcohol use, and femoral neck BMD.^1,6

Why the same label can mean different things

What your clinician may review

Risk factors that can matter

Several risk factors and secondary causes can sit behind low bone mass. These do not prove that someone will fracture, but they help decide whether osteopenia deserves a closer look.¹

• Family history, thin body habitus, Caucasian or Asian heritage, early menopause, irregular or absent periods, or hypogonadism.
• Low lifelong calcium intake, chronic vitamin D deficiency, low physical activity, immobilization, smoking, excessive alcohol, and high cola intake.
• Medications that may affect bone, including glucocorticoids, heparin, valproic acid, proton pump inhibitors, methotrexate, and excessive thyroid hormone replacement.
• Possible secondary causes such as hyperthyroidism, hyperparathyroidism, diabetes mellitus, celiac disease, inflammatory bowel disease, malabsorption, liver disease, rheumatoid arthritis, systemic lupus erythematosus, multiple myeloma, anorexia nervosa, and other medical conditions.

Lab tests that may be part of the workup

A careful clinical and laboratory evaluation can help explain why bone density is low. Common tests to discuss include calcium, phosphorus, albumin, alkaline phosphatase, liver function tests, creatinine, 25-hydroxyvitamin D, and TSH. In selected situations, clinicians may add testosterone testing in men, parathyroid hormone testing when calcium is elevated, or bone turnover markers.¹

This does not mean every person needs every test. It means the label “osteopenia” should not end the conversation. It should start a thoughtful search for the pieces that are relevant to the person in front of the clinician.

Prevention starts with the basics

Movement

Weight-bearing activity can help maintain and possibly improve BMD in the lumbar spine, sacral spine, and hip regions; walking 3 to 5 miles per week is one practical example. Walking alone may not be enough for every person or every skeletal site, so safe impact and resistance exercises can also be useful when matched to the person.¹

Calcium and vitamin D

Adequate calcium and vitamin D are cornerstones of prevention and treatment. Vitamin D deficiency can worsen osteopenia and osteoporosis, contribute to a mineralization problem in bone, and add muscle weakness and fall risk.^1,5

Because supplement needs depend on diet, age, kidney stone history, calcium level, vitamin D level, medications, and other health conditions, the safest patient step is to ask what target intake and blood level make sense for you rather than self-prescribing high doses.

Lifestyle and medication review

Bone-health basics also include avoiding smoking and excessive alcohol, minimizing medicines that harm bone when medically possible, and paying attention to fall risk, muscle strength, and balance.¹

When medication enters the conversation

Not everyone with osteopenia needs medication. Medication often enters the conversation for postmenopausal women and men age 50 or older with osteopenia when FRAX estimates a 10-year hip fracture probability of at least 3% or a 10-year major osteoporosis-related fracture probability of at least 20%.^1,3,4

Medication categories used in prevention or treatment conversations include bisphosphonates, estrogen or hormone therapy, selective estrogen receptor modulators, parathyroid hormone analog therapy, denosumab, and calcitonin. The right discussion depends on fracture risk, age, sex, menopause status, kidney function, digestive tolerance, cancer and clot history, prior fractures, side-effect profile, and personal preferences.¹

Questions to bring to your visit

• Do I have osteopenia by DXA only, osteoporosis by DXA, or a clinical diagnosis because of a fracture?
• Which DXA site should we use for decisions: spine, total hip, femoral neck, or forearm?
• Was FRAX calculated with femoral neck BMD, and what were my 10-year hip and major fracture risks?
• Do I have risk factors or secondary causes that should be checked?
• Should my vitamin D level, calcium intake, kidney function, thyroid status, or other labs be reviewed?
• What exercise is safe for me, especially if I have pain, balance problems, spine fracture history, or high fall risk?
• What would make medication worth discussing, and what are the expected benefits and tradeoffs?
• When should my DXA be repeated?

Evidence review

Biology

Osteopenia means bone density is lower than expected for a young healthy reference population, but it is not the same as saying a person has fragile bones today. Bone density is one part of strength; age, prior fracture, falls, medications, medical conditions, and rate of change matter.⁷¹⁰

Epidemiology and risk

Many fractures occur in people whose DXA result is in the osteopenia range, because osteopenia is common and fracture risk is driven by more than T-score alone. The useful question is not whether the label sounds mild, but whether the whole-person fracture risk is low, moderate, or high.⁷

Evaluation

Evaluation should confirm that the DXA is technically reliable, review prior fractures, estimate fracture probability when appropriate, and look for secondary contributors such as glucocorticoid exposure, endocrine disease, kidney disease, malabsorption, or other medication effects.⁹

Treatment strategy

Most people with osteopenia need a prevention plan rather than immediate medication: resistance and balance training, protein and calcium adequacy, vitamin D correction when deficient, fall-risk reduction, and repeat DXA timing based on baseline risk. Some people with osteopenia and high fracture probability, or a fragility fracture, may still merit medication discussion.⁸⁷

References

References below include the main osteopenia review and selected references cited in that review.

1. Karaguzel G, Holick MF. Diagnosis and treatment of osteopenia. Rev Endocr Metab Disord. 2010;11(4):237-251. doi:10.1007/s11154-010-9154-0.
2. El Maghraoui A, Roux C. DXA scanning in clinical practice. QJM. 2008;101(8):605-617. doi:10.1093/qjmed/hcn022.
3. Karaguzel G, Holick MF. Diagnosis and treatment of osteopenia. Rev Endocr Metab Disord. 2010;11(4):237-251. doi:10.1007/s11154-010-9154-0.
4. Kanis JA, Johansson H, Harvey NC, McCloskey EV. A brief history of FRAX. Arch Osteoporos. 2018;13(1):118. doi:10.1007/s11657-018-0510-0.
5. Hanley DA, Cranney A, Jones G, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ. 2010;182(12):E610-E618. doi:10.1503/cmaj.091062.
6. Kanis JA, Harvey NC, Johansson H, Liu E, Vandenput L, Lorentzon M, Leslie WD, McCloskey EV. A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res. 2020;32(2):187-196. doi:10.1007/s40520-019-01432-y.
7. Morin SN, Leslie WD, Schousboe JT. Osteoporosis: A Review. JAMA. 2025. doi:10.1001/jama.2025.6003. PMID:40587168.
8. Gourlay ML, Fine JP, Preisser JS, et al. Bone-Density Testing Interval and Transition to Osteoporosis in Older Women. N Engl J Med. 2012. doi:10.1056/NEJMoa1107142. PMID:22256806.
9. Ebeling PR, Nguyen HH, Aleksova J, Vincent AJ, Wong P, Milat F. Secondary Osteoporosis. Endocr Rev. 2022. doi:10.1210/endrev/bnab028. PMID:34476488.
10. Ye C, Ebeling P, Kline G. Osteoporosis. Lancet. 2025. doi:10.1016/S0140-6736(25)01385-6. PMID:40946719.